IL-21-mediated reversal of NK cell exhaustion facilitates anti-Tumour immunity in MHC class I-deficient tumours

Nature Communications

Volumn 8, Issue , 2017, Pages

  Seo, Hyungseok ^a   Jeon, Insu ^a   Kim, Byung Seok ^a   Park, Myunghwan ^a   Bae, Eun Ah ^a   Song, Boyeong ^a   Koh, Choong Hyun ^b   Shin, Kwang Soo ^b   Kim, Il Kyu ^a,b   Choi, Kiyoung ^c   Oh, Taegwon ^c   Min, Jiyoun ^d   Min, Byung Soh ^e   Han, Yoon Dae ^e   Kang, Suk Jo ^d   Shin, Sang Joon ^e   Chung, Yeonseok ^a   Kang, Chang Yuil ^a,b,c  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Cellid Inc   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA GALACTOSYLCERAMIDE; B CELL MONOCYTE LOADED TUMOR ANTIGEN ALPHA GALACTOSYLCERAMIDE VACCINE; CANCER VACCINE; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 21; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN DERIVATIVE; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

CANCER; CELLS AND CELL COMPONENTS; IMMUNITY; LIGAND; MAJOR HISTOCOMPATIBILITY COMPLEX; RODENT; TUMOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BLADDER CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INNATE IMMUNITY; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN DOMAIN; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; C57BL MOUSE; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; GENE; GENETICS; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; PATHOLOGY;

MUS;

ANIMALS; BIOMARKERS, TUMOR; CANCER VACCINES; COLORECTAL NEOPLASMS; GENES, MHC CLASS I; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MELANOMA; MICE, INBRED BALB C; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020455070     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15776     Document Type: Article

References (51)

1. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci.Transl. med. 8, 328rv324-328rv324 (2016).
2. Turcotte, S. et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J. Immunol. 191, 2217-2225 (2013).
3. Joncker, N. T., Shifrin, N., Delebecque, F. & Raulet, D. H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J. Exp. Med. 207, 2065-2072 (2010).
4. Ardolino, M. et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781-4794 (2014).
5. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
6. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-Tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
7. Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
8. Benson, D. M. et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010).
9. Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734-3743 (2012).
10. da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2, 410-422 (2014).
11. Pesce, S. et al. Identification of a subset of human NK cells expressing high levels of PD-1 receptor: A phenotypic and functional characterization J. Allergy Clin. Immunol. 139, 335-346 e333 (2017).
12. Leonard, W. J. & Wan, C.-K. IL-21 Signaling in Immunity. F1000Res. 5, 224 (2016).
13. Elsaesser, H., Sauer, K. & Brooks, D. G. IL-21 is required to control chronic viral infection. Science 324, 1569-1572 (2009).
14. Fröhlich, A. et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324, 1576-1580 (2009).
15. John, S. Y., Du, M. & Zajac, A. J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324, 1572-1576 (2009).
16. Takaki, R. et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175, 2167-2173 (2005).
17. Brady, J., Hayakawa, Y., Smyth, M. J. & Nutt, S. L. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172, 2048-2058 (2004).
18. Kasaian, M. T. et al. IL-21 limits NK cell responses and promotes antigenspecific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 16, 559-569 (2002).
19. Spolski, R. & Leonard, W. J. Interleukin-21: A double-edged sword with therapeutic potential. Nat. rev. Drug discov. 13, 379-395 (2014).
20. Chung, Y. et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 66, 6843-6850 (2006).
21. Ko, H. J. et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine. J. Immunol. 182, 1818-1828 (2009).
22. Kim, E.-K. et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 74, 6705-6716 (2014).
23. Liao, N.-S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 199-202 (1991).
24. Richter, J. et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121, 423-430 (2013).
25. Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126, 1224 (2016).
26. Zeestraten, E. et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br. j. cancer 110, 459-468 (2014).
27. Jin, H.-T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
28. Jiang, K. et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat. Immunol. 1, 419-425 (2000).
29. Coquet, J. M. et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178, 2827-2834 (2007).
30. Cui, J. et al. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997).
31. Huang, S. et al. Immune response in mice that lack the interferon-gamma receptor. Science 259, 1742-1745 (1993).
32. Zeng, R. et al. The molecular basis of IL-21-mediated proliferation. Blood 109, 4135-4142 (2007).
33. Rao, R. R., Li, Q., Bupp, M. R. G. & Shrikant, P. A. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation. Immunity 36, 374-387 (2012).
34. Deng, Y. et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity 42, 457-470 (2015).
35. Beldi-Ferchiou, A. et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7, 72961-72977 (2016).
36. Guillerey, C., Huntington, N. D. & Smyth, M. J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025-1036 (2016).
37. Shifrin, N., Raulet, D. H. & Ardolino, M. NK cell self tolerance, responsiveness and missing self recognition. Sem. Immunol. 26, 138-144 (2014).
38. Fauci, A. S., Mavilio, D. & Kottilil, S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5, 835-843 (2005).
39. Kumar, V. & McNerney, M. E. A new self: MHC-class-I-independent naturalkiller-cell self-Tolerance. Nat. Rev. Immunol. 5, 363-374 (2005).
40. Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265-278 (2015).
41. Roda, J. M. et al. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177, 120-129 (2006).
42. Jeong, W. I., Park, O., Radaeva, S. & Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441-1451 (2006).
43. Gotthardt, D. et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124, 2370-2379 (2014).
44. Wei, S. et al. Control of lytic function by mitogen-Activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J. Exp. Med. 187, 1753-1765 (1998).
45. Vivier, E., Nunes, J. A. & Vely, F. Natural killer cell signaling pathways. Science 306, 1517-1519 (2004).
46. Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
47. Zhu, E. F. et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-Tumor antigen antibodies and extended serum half-life IL-2. Cancer cell 27, 489-501 (2015).
48. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396-401 (2016).
49. Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402-1410 (2016).
50. Sutherland, A. P. et al. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J. Immunol. 190, 3977-3984 (2013).
51. Kim, E.-K. et al. Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures. Gene Ther. 21, 106-114 (2014).